Relmada Therapeutics, Inc. (RLMD)

Market Cap	84.49M
Revenue (ttm)	n/a
Net Income (ttm)	-86.49M
Shares Out	30.17M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142,164
Open	2.850
Previous Close	2.750
Day's Range	2.750 - 2.970
52-Week Range	1.880 - 7.220
Beta	0.41
Analysts	Hold
Price Target	7.50 (+167.86%)
Earnings Date	Nov 7, 2024

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Forecast

According to 2 analysts, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 167.86% from the latest price.

Price Target

$7.5

(167.86% upside)

Analyst Consensus: Hold